tbuckley/cabot-search huggingface dataset:
Serum iron levels as a predictive factor in FOLFOX/FOLFIRI therapy.
Authors: T. Ochiai, K. Nishimura, T. Watanabe, M. Kitajima, T. Hashiguchi, A. Nakatani, N. Sakuyama, T. Uchida, T. Sato, K. Kishine, S. Futagawa, I. Nagaoka
Journal: Journal of Clinical Oncology (2011)

e14141 Background: Recently, it was reported that iron reduction was associated with lower cancer risk and mortality (Zacharski et al, J NATL CANCER I 2008). An increase in serum iron levels after administration of various anticancer drugs was reported (Follezou et al, NEOPLASMA 1985). We have also reported an increase in serum iron levels during FOLFOX and FOLFIRI therapies (ASCO 2009: #e15110). The aim of this study was to evaluate the correlation between prognosis and serum iron levels in advanced colorectal cancer (CRC) patients treated with FOLFOX ± bevacizumab (Bev) or FOLFIRI ± Bev. Methods: Serum iron, hemoglobin, AST and ALT serum levels were measured before and at 48 hr after treatment (FOLFOX4 ± Bev, FOLFIRI ± Bev, or FOLFIRI + cetuximab [Cet]) in 47 advanced CRC patients, all of whom died between Dec. 2005 and Sep. 2010. Using the median rate of increase in serum iron levels as the cut-off value in each therapy, these patients were categorized into a high group (increase rate over cut-off value in at least one therapy) and a low group (increase rate under the cut-off value in all therapies). Prognosis was evaluated between the 2 groups using the Kaplan-Meier method and the log rank test. Results: No significant changes in hemoglobin, AST or ALT serum levels were observed during treatment. Serum iron levels transiently increased at after treatment (48 hr), then returning to baseline within 2 weeks. Median rate of increase in serum iron levels at before and at 48 hr after FOLFOX4, FOLFIRI, FOLFOX4 + Bev, FOLFIRI + Bev, or FOLFIRI + Cet therapies was 217%, 348%, 200%, 434% and 344%, respectively, showing a significant increase (p<0.001). Median survival time (MST) in the high group (n: 28) and low group (n: 19) was 421.5 and 351 days, respectively. The MST was significantly better in the high group (p=0.036). Conclusions: The results suggest that transient increases in serum iron levels are not due to destruction of hepatocytes or erythrocytes. The significantly better prognosis in the high group suggests that serum iron levels could be used as a predictive factor in FOLFOX/FOLFIRI therapy.
P245 Whole blood levels of microrna-34a predict survival and regulate genes associated with pulmonary arterial hypertension
Authors: J Lin, J Iremonger, J Pickworth, A Rothman, H Casbolt, N Arnold, C Elliot, R Condliffe, D Kiely, A Lawrie
Journal: Thorax (2016)

<h3>Introduction</h3> Despite advanced therapies for pulmonary arterial hypertension (PAH), the hyperproliferative pulmonary vasculopathy persists. Circulatory microRNAs (miR) offer considerable promise as both a prognostic biomarker, and to identify molecular mechanisms underlying PAH. Previous study from our lab identified whole blood miR-34a as downregulated in patients with PAH. <h3>Objectives</h3> To validate changes in whole blood miR-34a levels in patients with PAH and relate them to disease severity and survival, and determine the phenotypic effect on pulmonary artery smooth muscle cells (PASMC). <h3>Methods</h3> Whole blood RNA was isolated from 27 treatment-naive patients with PAH, 12 age-matched healthy volunteers (HV) and experimental models of PAH (Monocrotaline-MCT, Sugen5416/hypoxia-SuHx and controls, n = 5/group). Whole blood miR-34a-5p and −3p levels were measured by qPCR. The phenotypic effect of miR-34a-5p and −3p levels was assessed on PASMC <i>in-vitro</i>. Differences between groups were determined by Student’s t-test or ANOVA-Tukey. <h3>Results</h3> Whole blood miR-34a-5p was reduced in patients with PAH (p &lt; 0.0001) and experimental models of PAH (MCT p &lt; 0.05, SuHx p &lt; 0.001). Receiver operating characteristic curve identified that miR-34a-5p levels discriminates patients with PAH from HV (AUC = 0.86, p = 0.001). MiR-34a-5p levels were significantly lower in patients with severe PAH, as defined by a cardiac index of &lt;2 vs &gt;2.5 l/min/m<sup>2</sup> (p &lt; 0.05) and NT-proBNP &gt; 300 vs &lt;300 ng/l (p &lt; 0.001) and predict survival at 5 years. MiR-34a-5p levels were negatively correlated with pulmonary vascular resistance (r = −0.4, p &lt; 0.05) and pulmonary arterial wedge pressure (r = −0.4, p &lt; 0.05). Preliminary data showed that whole blood miR-34a-3p was reduced in patients with PAH (p = 0.0267) and experimental models of PAH (MCT p &lt; 0.01, SuHx p &lt; 0.01); and delineates patients with PAH from HV (AUC = 0.925, P = 0.01). Transfection of PDGF-stimulated PASMC with miR-34a-5p or −3p inhibitor promote PASMC proliferation (p &lt; 0.001). In contrast, miR-34a-5p and −3p mimic suppress PASMC proliferation (p &lt; 0.05 and p &lt; 0.001 respectively). Additionally, transfection with miR-34a-3p increases caspase-3/7 activities in PASMC (p &lt; 0.0001). <h3>Conclusions</h3> Reduced miR-34a-5p levels associate with increased disease severity and poor prognosis in PAH. MiR-34a-5p and −3p levels regulate PASMC proliferative-phenotype in response to PDGF. This research identifies miR-34a-5p and −3p as potential biomarkers, subsequent network analysis may identify novel disease mechanisms. Further experiments in preclinical models are currently underway.
P38 Repeatability of structured light plethysmography (slp) for measurement of respiratory rate in normal subjects
Authors: R Iles, W De Boer, A Khalid, S Motamedi Fakhr, R Wilson
Journal: Thorax (2016)

<h3>Introduction</h3> Structured Light Plethysmography (SLP) captures movements of a light grid projected onto the thoraco-abdominal (TA) wall to produce a waveform from which a primary derived output is Respiratory Rate (RR). Assessment of repeatability is essential for clinical use, however, physiological variability can confound results. RR agrees within ± 2 breaths per minute (brpm)<sup>1</sup> with Respiratory Inductance Plethysmography (RIP) measured simultaneously on one occasion. We propose that if measurements are repeatable, there would be no difference in agreement between devices over a series of sessions. <h3>Aim</h3> This study assessed repeatability of the agreement between SLP and RIP. <h3>Methods</h3> 14 subjects (7 male, 7 female) with no respiratory diagnosis underwent 5 minutes of simultaneous measurement with SLP and RIP during quiet breathing. This was repeated on 3 occasions over 2 days, by the same operator, at the same location and using the same devices. RR were calculated for thorax ( THRR), abdomen (ABRR) and the entire thoraco-abdominal (TARR) signals for both devices. Agreement between the two devices was assessed using Bland-Altman plots with LOA set at &lt; ± 2 breaths/min. <h3>Results</h3> For TARR and THRR, all points were within 2 SD of the mean; for ABRR, 1 of 14 points was outside of 2 SD, but the LOA were within &lt; ± 2 breaths/min. The mean differences between the two devices were 0.476, 0.605 and 0.524 breaths/min for TARR, THRR and ABRR, respectively. <h3>Conclusion</h3> Agreement was observed between the two devices for each set of repeated measurements. We conclude that measurement of RR are repeatable. <h3>Reference</h3> Iles R, <i>et al</i>. American Thoracic Society Meeting 2014,A2935.
High Throughput Screening Identifies Potential Inhibitors of WHSC1/MMSET, a Histone Methyltransferase Oncoprotein in Multiple Myeloma and Acute Lymphocytic Leukemia
Authors: Christine M Will, Michael Scholle, Roodolph St. Pierre, Gary Schiltz, James E. Bradner, Milan Mrksich, Jonathan D. Licht
Journal: Blood (2015)
Naturally Occurring Regulatory T Cells Modulate Immune Responses Against Exogenous Factor VIII in Hemophilic Balb/c Mice but Not in C57BL/6J Mice.
Authors: Christina Hausl, Josenato Ilas, Christian Lubich, Rafi U. Ahmad, Eva M. Muchitsch, Hartmut Ehrlich, Hans Peter Schwarz, Birgit M. Reipert
Journal: Blood (2007)
P104 Results of the first analysis of national lung cancer audit data based on cancer registration data
Authors: P Beckett, A Khakwani, R Hubbard, S Vernon, R Jack, N Wood, B Plewa, N McAndrew, R Dickinson, N Navani, S Harden, I Woolhouse
Journal: Thorax (2016)

<h3>Introduction</h3> The National Lung Cancer Audit (NLCA) has collected data for over 10 years, but in early 2015 a transition to using the Cancer Outcomes and Services Dataset (COSD) and cancer registration was begun and has now entirely superseded the legacy LUCADA dataset. An online portal (CancerStats) has been developed with a bespoke section providing near real time analysis of unprocessed COSD data for the NLCA. This portal currently focusses on data completeness, with plans to add process and treatment data in the near future. We report the results of the first 12 months of data collection using the new system (2015), and have compared this to the last year of LUCADA submissions (2014). <h3>Methods</h3> The COSD was submitted monthly by English trusts on patients diagnosed with invasive lung cancer throughout 2015. This raw data was used to populate the data completeness tables on the CancerStats portal. An algorithm was developed to allocate a “trust first seen” to each patient record. Our presentation will include data from the final processed cancer registration records that have been validated using all available data sources within the National Cancer Registration Service (NCRAS). Welsh data submitted via their CANISC system will be available for our presentation. <h3>Results</h3> 35,000 individual cases of invasive lung cancer were submitted by English Trusts. Data completeness results are shown in Table 1. Our final presentation will be updated with data from the processed cancer registration records that have been validated using all available data sources within the National Cancer Registration Service (NCRAS), as well as results from Welsh trusts. <h3>Conclusion</h3> COSD submissions appear to capture more cases of lung cancer than LUCADA. During this transition period, the quality of the data was less good than previous years with significant variation across organisations. However, data completeness for stage and treatment is expected to be better than indicated since final registered cases use data from a variety of other sources. CancerStats offers the opportunity for teams to monitor their data quality and to iteratively improve their internal processes to deliver robust data for future years, in particular patient factors such as performance status which is not available elsewhere.
p53 Deletion Yields High Response Rates but Rapid Progression and Poor Overall Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Authors: Joseph R. Mikhael, Jodi Goodwin, Xiaoying Qi, Wei Xu, Keith Stewart, Donna Reece, Christine Chen, Suzanne Trudel, Vishal Kukreti, Hong Chang
Journal: Blood (2007)
P111 Older patients with tuberculosis have less typical changes on chest radiographs
Authors: A Abbara, Z Mahomed, SM Collin, OM Kon, V Bushell, K Buell, JAL Sullivan, T Hansel, T Corrah, RN Davidson
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> It has been suggested that TB has a different phenotype in older patients with age-related changes to the cell-mediated immune response and co-existent organ dysfunction. Older patients with tuberculosis (TB) may have different radiographic features than younger patients; this may lead to less immediate suspicion of TB resulting in delays to diagnosis and starting treatment. We wanted to identify if there are differences in the most common radiological differences in older and younger patients with pulmonary TB (PTB). <h3>Methods</h3> Patients with PTB &gt; 65 were noted from the London TB register between 2002 and 2015. A random selection of younger patients aged 18–40 with PTB were also identified. All available chest x-ray (CXR) reports were obtained from online radiology systems. CXR features were classified according to reported features with particular note of cavitation, nodules and miliary changes, consolidation, lymphadenopathy and effusions. <h3>Results</h3> The CXR reports of 239 patients with PTB &lt; 65 and 99 patients with PTB &gt; 65 were collated. Demographic details as well as CXR changes are detailed in Table 1. Cavitation, lymphadenopathy and effusions were more common in younger patients whereas consolidation was more evident in older patients. Upper zone involvement was similar in both groups. <h3>Conclusions</h3> Studies by other groups have suggested a higher proportion of cavitation and upper zone changes in younger patients with TB with less specific changes in older patients. This may lead to less suspicion of TB and potentially a longer infective period; this is important given that 23% and 19% of younger and older patients have smear positive PTB. In our study, the proportion with upper zone changes are similar though cavitation is more frequent in younger patients. Of note, is the much higher presence of lymphadenopathy and effusions seen in younger patients. This may potentially be related to differences in the immune function of both groups or primary infection versus reactivation. These findings re-enforce the need for clinical suspicion for PTB in both older and younger patients with both specific and non-specific radiographic changes.
Symptoms, signs, suspicion and setting: a PESI score for cancer-associated pulmonary embolism?
Authors: Florian Posch, Cihan Ay
Journal: European Respiratory Journal (2017)

Pulmonary embolism (PE) is a frequent complication in patients with cancer [1]. In contrast to PE in non-cancer patients, a considerable proportion of those in the oncological setting is detected incidentally on routine computed tomography (CT) staging/restaging examinations in asymptomatic (or, in hindsight, often oligosymptomatic) patients [2]. Different terminologies for this phenomenon exist in the literature, including unsuspected, incidental, and asymptomatic PE, with asymptomatic PE being clearly not preferable as many patients do report symptoms in retrospect [3]. Managing these so-called unsuspected pulmonary embolisms (UPEs) is a major challenge, because the clinical implications of this ill-defined condition are not fully understood and optimal therapeutic strategies are unclear [4, 5]. In this issue of the European Respiratory Journal , Font et al. [6] report observational evidence from the Spanish ambispective EPIPHANY registry, which has some relevance to the emerging topic of UPE. This is one of the few studies specifically dedicated to cancer-associated PE [2], and the analysis included subject-level data on anticoagulation, recurrent thrombosis and death from more than 1000 patients with this condition, rendering it one of the largest studies to date in the field. The investigators identified distinct patterns of 30-day mortality depending on whether patients had PE that was clinically suspected or not, and did or did not present with symptoms and/or signs suggestive of PE at the time of routine CT imaging performed for reasons other than PE diagnosis. These patterns prompted the investigators to derive a new three-level empiric classification of cancer-associated PE, which distinguishes the three scenarios 1) suspected pulmonary embolism (SPE), 2) truly asymptomatic UPE (TA-UPE) and 3) UPE with symptoms (UPE-S). Two risk classification schemes for cancer-associated PE have already been developed [7, 8]. What is the added value of this one? Is this new classification relevant for clinical decision making? And should it be adopted in the management of patients with cancer-associated PE? Suspect it or not: a call for assessing the severity of cancer-associated pulmonary embolism <http://ow.ly/VvAB3079LFZ>
P1.06-033 Non-Small Cell Lung Cancer in Young Patients; Clinico-Pathologic Criteria and Prognostic Factors
Authors: M. Rahouma, Hala Aziz, Fatma Abou Elkassem, Iman Loay, Galal Ghaly, Mohamed Kamel, Abdelrahman Abdelrahman
Journal: Journal of Thoracic Oncology (2017)
Constitutive gp130-JAK-STAT3 Signaling Induces a Plasma Cell Disorder Representing Genetic and Clinical Features of Human Myeloma – a Novel in Vivo Model for the Patient Subgroup Characterized By a STAT3 Target Gene Signature
Authors: Sabine Steidle, Tobias Dechow, Katharina Götze, Martina Rudelius, Konstanze Pechloff, Kerstin Behnke, Lars Bullinger, Falko Fend, Soberon Valeria, Marc Schmidt-Supprian, Florian Bassermann, Jürgen Ruland, Christian Peschel, Ulrich Keller
Journal: Blood (2014)
MA10.07 18F-Fluorodeoxyglucose Positron Emission Tomography Scan in Solid-Type Stage-I Pulmonary Adenocarcinomas: What Cause False-Negative Cases?
Authors: Filippo Lococo, Carla Galeone, Debora Formisano, Salvatore Bellafiore, Angelina Filice, Annunziata Tartaglione, Alfredo Cesario, Cristian Rapicetta, Federica Fioroni, Tommaso Ricchetti, Massimiliano Paci
Journal: Journal of Thoracic Oncology (2017)
Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)
Authors: David S. Siegel, Jesus G. Berdeja, Jeffrey R. Infante, Jonathan L. Kaufman, Michael (Luhua) Wang, Thomas G. Martin, Ruben Niesvizky, Frederic J. Reu, Sundar Jagannath, Kanya Rajangam, Mei Huang, Ravi Vij
Journal: Blood (2014)
Haploidentical Hematopoietic Stem Cell Transplantation in Children Leukemia and Lymphoma with G-CSF Mobilized Marrow Grafts without T Cell Depletion: A Single Center Report of 45 Cases.
Authors: HengXiang Wang, Hong-Min Yan, Lian-Ning Duan, Ling Zhu, Mei Xue, Jing Liu
Journal: Blood (2008)
Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.
Authors: Aristeidis Chaidos, Chrissy Giles, Holger W Auner, Marco Bua, Jiri Pavlu, Ellena Smith, Edward Kanfer, Donald MacDonald, Jane F. Apperley, Amin Rahemtulla
Journal: Blood (2009)
P1.01-004 Is There Any Role of Residential Radon in Non-Small Cell Lung Cancer (NSCLC) Patients Harboring Molecular Alterations?
Authors: Laura Mezquita, Amparo Benito, Maria Eugenia Olmedo, Pablo Reguera, Ainhoa Madariaga, Maria Villamayor, Silvia Patricia Cortez, Luis Gorospe, Almudena Santon, Sagrario Mayoralas, Raul Hernanz, Alberto Cabanero, Alfredo Carrato, Pilar Garrido
Journal: Journal of Thoracic Oncology (2017)
Tunnel and clip endoscopic submucosal dissection of a pharyngeal superficial squamous cell carcinoma detected with narrow-band imaging
Authors: Jérémie Jacques, Jérôme Rivory, Vincent Lépilliez, Leslie Rinaldi, Jean-Christophe Saurin, Thierry Ponchon, Mathieu Pioche
Journal: Endoscopy (2017)

Patients with squamous cell carcinoma (SCC) of the esophagus must be screened for synchronous and metachronous lesions of the head and neck during surveillance. Screening by head and neck surgeons is performed using high definition resolution (HDR) endoscopy and narrow-band imaging (NBI), which aid considerably in the detection of superficial lesions.
P1.02-053 Comparison of Two Different Commercially Available Probes for the Detection of ALK Rearrangements in Cytological Smears
Authors: Maria Lozano Escario, Mercedes Aguirre, Maria Eugenia Echarri, Jose Echeveste, Nerea Gomez, Maria Amada Maset, Marta Abengozar, Luis Mejias, Alfonso Gurpide, Salvador Martin-Algarra
Journal: Journal of Thoracic Oncology (2017)
<i>Escherichia coli</i>O157:H7 Infections Associated with Contaminated Pork Products — Alberta, Canada, July–October 2014
Authors: Lance Honish, Nisha Punja, Sarah Nunn, Dale Nelson, Nyall Hislop, Garth Gosselin, Natisha Stashko, Darlene Dittrich
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

During July-October 2014, an outbreak of 119 Escherichia coli O157:H7 infections in Alberta, Canada was identified through notifiable disease surveillance and investigated by local, provincial, and federal public health and food regulatory agencies. Twenty-three (19%) patients were hospitalized, six of whom developed hemolytic uremic syndrome; no deaths were reported. Informed by case interviews, seven potential food sources were identified and investigated. The majority of patients reported having consumed meals containing pork at Asian-style restaurants in multiple geographically diverse Alberta cities during their exposure period. Traceback investigations revealed a complex pork production and distribution chain entirely within Alberta. E. coli O157:H7-contaminated pork and pork production environments and mishandling of pork products were identified at all key points in the chain, including slaughter, processor, retail, and restaurant facilities. An outbreak-specific pulsed-field gel electrophoresis (PFGE) cluster pattern was found in clinical and pork E. coli O157:H7 isolates. Measures to mitigate the risk for exposure and illness included pork product recalls, destruction of pork products, temporary food facility closures, targeted interventions to mitigate improper pork-handling practices identified at implicated food facilities, and prosecution of a food facility operator. Pork should be considered a potential source in E. coli O157:H7 investigations and prevention messaging, and pork handling and cooking practices should be carefully assessed during regulatory food facility inspections.
Interferon Treatment for Dilated Cardiomyopathy and Striated Myopathy Associated With Hepatitis C Virus Infection Based on Serial Measurements of Serum Concentrations of Cardiac Troponin T
Authors: Yukihito Sato, Yoshiki Takatsu, Tasuku Yamada, Kazuaki Kataoka, Ryoji Taniguchi, Rokuro Mimura, Shigetake Sasayama, Akira Matsumori
Journal: Circulation (2000)

The present authors recently suggested, on the basis of studies using polymerase chain reaction (PCR), that hepatitis C virus (HCV) infection is involved in the etiology or pathogenesis of cardiomyopathic disorders. They have also reported that the serum concentration of cardiac troponin T is an indicator of ongoing myocyte degeneration in patients with dilated cardiomyopathy (DCM) and hypothesized that its serial measurement may be a marker of therapeutic efficacy. This is the first case report of DCM and striated myopathy, associated with HCV infection, treated with interferon therapy guided by monitoring of serial serum concentrations of cardiac troponin T. Positive-plus strands of HCV RNA were found in the patient's myocardium, as well as plus and minus strands in the quadriceps muscle specimens. Serum levels of creatine kinase (CK), CK-MB and cardiac troponin T fell as serum HCV titers decreased during treatment with interferon, whereas conventional treatment of heart failure had no effect. Monitoring of serial serum concentrations of cardiac troponin T may allow the earlier diagnosis and treatment of patients with HCV-associated cardiomyopathy and improve their clinical course.
FREE FATTY ACIDS REPRESS SHP ACTIVATION AND ADIPONECTIN COUNTERACTS BILE ACID INDUCED LIVER INJURY
Authors: Lars Bechmann, Peri Kocabayoglu, Jan-Peter Sowa, Svenja Sydor, Johannes Schmitt, Rebekka Hannivoort, Juergen Treckmann, Christian Rust, Guido Gerken, Andreas Geier, Ali Canbay
Journal: Hepatology (2011)
Risk of inflammatory bowel disease in patients with rosacea: Results from a nationwide cohort study in Taiwan
Authors: Chun-Ying Wu, Yun-Ting Chang, Chao-Keui Juan, Jeng-Jer Shieh, Yu-Pu Lin, Han-Nan Liu, Jaw-Town Lin, Yi-Ju Chen
Journal: Journal of the American Academy of Dermatology (2017)
Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era
Authors: Andrew M Evens, Jennifer A. Kanakry, Laurie H. Sehn, Tatyana Feldman, Aimee Kroll, Randy D. Gascoyne, Adam M. Petrich, Jeremy S. Abramson, Francisco J. Hernandez-Ilizaliturri, Zeina Al-Mansour, Camille Adeimy, Jessica Hemminger, Nancy L. Bartlett, Anthony Mato, Paolo F. Caimi, Ranjana H. Advani, Andreas K. Klein, Izidore S Lossos, Oliver W. Press, Jonathan W. Friedberg, Julie M Vose, Kristie A. Blum
Journal: Blood (2013)